Claims for Patent: 6,923,983

Summary for Patent: 6,923,983

Title:	Transdermal delivery of hormones
Abstract:	The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention
Inventor(s):	Morgan; Timothy Matthias (Carlton North, AU), Bakalova; Margarita Vladislavova (Bundoora, AU), Klose; Karthryn Traci-Jane (Chelsea, AU), Finnin; Barrie Charles (Glen Iris, AU), Reed; Barry Leonard (Strathmore, AU)
Assignee:	Acrux DDS PTY LTD (Victoria, AU)
Application Number:	10/428,018
Patent Claims:	1. A transdermal drug delivery system comprising: (a) a therapeutically effective amount of a hormone; (b) at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen of formula (I): ##STR2## wherein R.sup.1 is hydrogen, lower alkyl, lower alkoxy, halide, hydroxy or NR.sup.3 R.sup.4 ; R.sup.2 is a C.sub.8 to C.sub.18 alkyl; R.sup.3 and R.sup.4 are each independently hydrogen, lower alkyl or R.sup.3 and R.sup.4 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring; n is 0 or 1, and q is 1 or 2, wherein, when n is 0 and R.sup.1 is NR.sup.3 R.sup.4, then NR.sup.3 R.sup.4 is para-substituted, and wherein said dermal penetration enhancer is present in an amount of from about 10 to about 10,000 wt % based on the weight of the hormone; and (c) at least one volatile liquid. 2. The transdermal drug delivery system according to claim 1, wherein said dermal penetration enhancer is octyl salicylate. 3. The transdermal drug delivery system according to claim 1, wherein said volatile liquid is selected from the group consisting of ethanol, isopropanol, and a mixture thereof. 4. The transdermal drug delivery system according to claim 1, comprising on a weight basis: (a) from about 0.1 to about 10% of said hormone; (b) from about 0.1 to about 12% of said at least one dermal penetration enhancer; and (c) from about 78 to about 99.8% of said volatile liquid. 5. The transdermal drug delivery system according to claim 1, wherein the hormone is selected from the group consisting of levonorgestrel, gestodene, oestriol, oestrone, mestranol, stilboestrol, dienoestrol, epioestriol, estropipate, zeranol, allyloestrenol, dydrogesterone, lynoestrenol, norgestrel, norethyndrel, norethisterone, medroxyprogesterone, and megestrol. 6. The transdermal drug delivery system according to claim 1, wherein the hormone is levonorgestrel. 7. The transdermal drug delivery system according to claim 1, wherein the hormone is selected from the group consisting of nestorone and MENT (7-methyl-19-testoserone). 8. The transdermal drug delivery system according to claim 1, wherein the hormone is selected from the group consisting of ethinyloestradiol, progesterone, oestradiol, norethisterone acetate, and testosterone. 9. The transdermal drug delivery system according to claim 8, comprising on a weight basis: (a) from about 0.1 to about 10% oestradiol; (b) from about 1 to about 12% octyl salicylate; and (c) from about 78 to about 99.8% Alcohol USP (95% ethanol). 10. The transdermal drug delivery system according to claim 8, comprising on a weight basis: (a) from about 1 to about 3% oestradiol; (b) from about 1 to about 12% octyl salicylate; (c) from about 45 to about 90% of a volatile liquid selected from the group consisting of ethanol, isopropanol, and a mixture thereof; (d) from about 5 to about 45% water; and (e) from about 0.5 to about 5% of a thickening agent. 11. A method for administering at least one systemic hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system according to claim 1. 12. The method according to claim 11, wherein the hormone is selected from the group consisting of levonorgestrel, gestodene, oestriol, oestrone, mestranol, stilboestrol, dienoestrol, epioestriol, estropipate, zeranol, allyloestrenol, dydrogesterone, lynoestrenol, norgestrel, norethyndrel, norethisterone, medroxyprogesterone, and megestrol. 13. The method according to claim 12, wherein the hormone is levonorgestrel. 14. The method according to claim 11, wherein the hormone is selected from the group consisting of nestorone and MENT (7-methyl-19-testoserone). 15. The method according to claim 11, wherein the hormone is selected from the group consisting of ethinyloestradiol, progesterone, oestradiol, norethisterone acetate, and testosterone. 16. The method according to claim 11, wherein the hormone is oestradiol. 17. The method according to claim 11, wherein the drug delivery system is applied to the skin of the animal covering a delivery surface area between about 10 and 800 cm.sup.2. 18. The method according to claim 11, wherein the drug delivery system is applied to the skin of the animal covering a delivery surface area between about 10 and 400 cm.sup.2. 19. The method according to claim 11, wherein the drug delivery system is applied to the skin of the animal covering a delivery surface area between about 10 and 200 cm.sup.2. 20. The method according to claim 11, wherein the drug delivery system is applied using a fixed or variable metered dose applicator.